Legend Biotech (NASDAQ:LEGN – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Legend Biotech to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends.
Risk and Volatility
Legend Biotech has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Legend Biotech’s peers have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Legend Biotech and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Legend Biotech | $1.36 billion | -$296.80 million | -1,750.00 |
| Legend Biotech Competitors | $750.99 million | $11.63 million | -18.78 |
Legend Biotech has higher revenue, but lower earnings than its peers. Legend Biotech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations for Legend Biotech and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Legend Biotech | 1 | 6 | 9 | 0 | 2.50 |
| Legend Biotech Competitors | 9923 | 15313 | 45667 | 1602 | 2.54 |
Legend Biotech presently has a consensus price target of $50.85, suggesting a potential upside of 190.55%. As a group, “Biotechnology” companies have a potential upside of 126.35%. Given Legend Biotech’s higher possible upside, research analysts plainly believe Legend Biotech is more favorable than its peers.
Profitability
This table compares Legend Biotech and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Legend Biotech | -0.02% | -0.03% | -0.02% |
| Legend Biotech Competitors | -12,224.09% | -202.33% | -31.23% |
Summary
Legend Biotech beats its peers on 7 of the 13 factors compared.
Legend Biotech Company Profile
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
